Dennis Dong Hwan Kim
Overview
Explore the profile of Dennis Dong Hwan Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Araujo J, Wagenblast E, Voisin V, McLeod J, Gan O, Bansal S, et al.
Blood
. 2025 Jan;
PMID: 39841016
Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and relapse, but therapies tailored towards eradicating LSCs without harming normal hematopoietic stem cells (HSCs) are lacking. FLT3 is considered...
2.
Alnughmush A, Sayyed A, Remberger M, Al-Shaibani E, Chen C, Chiarello C, et al.
Transplant Direct
. 2025 Jan;
11(2):e1753.
PMID: 39802196
Background: Despite decades of post-allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been...
3.
Szuber N, Machado L, Kim D
Future Oncol
. 2025 Jan;
21(4):409-419.
PMID: 39780692
No abstract available.
4.
Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al.
Blood Adv
. 2024 Nov;
9(3):660-669.
PMID: 39565954
Posttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) transplants...
5.
DeFilipp Z, Fox L, Holderried T, Mehra V, Michonneau D, Pashley A, et al.
Transplant Cell Ther
. 2024 Nov;
31(2):76.e1-76.e13.
PMID: 39536878
The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review...
6.
Desai N, Viswabandya A, Kim D, Lipton J, Mattsson J, Law A
Eur J Haematol
. 2024 Nov;
114(2):310-314.
PMID: 39494777
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti-donor isohemagglutinins leads...
7.
Hochhaus A, Wang J, Kim D, Kim D, Mayer J, Goh Y, et al.
N Engl J Med
. 2024 May;
391(10):885-898.
PMID: 38820078
Background: Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better...
8.
Pasic I, Alfaro Moya T, Remberger M, Chen C, Gerbitz A, Kim D, et al.
Transplant Cell Ther
. 2024 Apr;
30(7):681.e1-681.e11.
PMID: 38648898
Treosulfan has shown promise in allogeneic hematopoietic cell transplantation (HCT) for its myeloablative properties and low toxicity. In this single-center retrospective propensity score-matched cohort study we compared treosulfan- and busulfan-based...
9.
Song G, Kim H, Kim T, Ahn S, Jung S, Kim M, et al.
Sci Rep
. 2024 Apr;
14(1):8517.
PMID: 38609396
This study aimed to validate the 2022 European LeukemiaNet (ELN) risk stratification for acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to 2014 were...
10.
Kim D, Popradi G, Lepic K, Paulson K, Allan D, Vasudevan Nampoothiri R, et al.
Curr Oncol
. 2024 Mar;
31(3):1426-1444.
PMID: 38534941
This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada...